Services at Banner MD Anderson Cancer Center  

Clinical Trial Listing

 

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.For more information about these trials please visit ClinicalTrials.gov.


Open for Accrual Clinical Trials

Breast Cancer

Colorectal Cancer

Lung Cancer

Lymphoma

Pancreatic Cancer

Stem Cell Transplant

(back to top)


 Active Clinical Trials

Cancer Type Name of Study Identifier # Principal Investigator
Breast Cancer An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer

NCT01698918

Dr. Mary Cianfrocca
Breast Cancer A Radomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combo with Carbo and Paclitaxel vs. Placebo Plus Carb and Paclitaxal in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609

Dr. Mary Cianfrocca
Breast Cancer Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer NCT01266642 Dr. Emily Grade
Colorectal Cancer A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy NCT01478594 Dr. Tomislav Dragovich
Lung Cancer A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT01846416 Dr. Klaus Wagner
Lung Cancer An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) NCT02041533 Dr. Klaus Wagner
Melanoma A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma NCT01511913 Dr. Jade Homsi
Melanoma Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma NCT01844505 Dr. Jade Homsi
Melanoma Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma NCT01597908 Dr. Jade Homsi
Lymphoma Phase III Randomized, Open Label Study of Single Agent  Ofatumumab vs Single Agent Rituximab in Follicular Lymphoma Relapsed After  Rituximab-Containing Therapy NCT01200589 Dr. Uwe Klueppelberg
Ovarian Cancer MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer NCT01091428 Dr. Matthew Schlumbrecht
Renal Cell A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy NCT01865747 Dr. Bryan Wong

(back to top)


Closed Clinical Trials

Leukemia

Cancer Type Name of Study Identifier # Principal Investigator
Bladder Cancer Multi-center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients with Advanced/Metastatic Refractory Urothelial Carcinoma  NCT01331824 Dr. Bryan Wong
Breast Cancer A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast Cancer

NCT01989676

Dr. Shakeela Bahadur
Leukemia Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting NCT01244750 Dr. Uwe Klueppelberg
Leukemia Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy  NCT01039376 Dr. Uwe Klueppelberg
Lung Cancer Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC NCT01947608 Dr. Klaus Wagner
Pancreatic Cancer Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer NCT01494506 Dr. Tomislav Dragovich

(back to top)

Banner MD Anderson Cancer Center
Higley Road and US 60
2946 E. Banner Gateway Drive
Gilbert, AZ 85234
(480) 256-6444
(855) 256-6444

Follow Us:  
Facebook IconPinterestTwitter IconBlogYouTube Icon
 
 
 
Jump to top links